Go Deep
Aristo Bio-Tech and Lifescience Limited
Aristo Bio-Tech and Lifescience Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 21,386 | 8.4 | 1.63 | 0.80 | 89.15 |
| Sep 2026 | 21,386 | 8.4 | 1.63 | 0.80 | 89.15 |
| Sep 2026 | 20,692 | 8.9 | 1.83 | 0.80 | 100.60 |
| Oct 2026 | 24,561 | 8.4 | 1.68 | 0.80 | 92.00 |
| Oct 2026 | 23,411 | 8.4 | 1.71 | 0.80 | 94.00 |
| Oct 2026 | 24,129 | 8.4 | 1.38 | 0.80 | 89.30 |
Aristo Bio-Tech and Lifescience Limited Quarterly Results
Quarterly data isn't available for this company right now.
Aristo Bio-Tech and Lifescience Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 3,637,171,000.0 | 3,180,926,000.0 | 2,451,479,000.0 | 2,178,555,000.0 | — |
| Net Profit | 71,826,000.0 | 40,631,000.0 | 38,957,000.0 | 35,622,000.0 | — |
| EPS | — | 6.0 | 5.7 | 6.7 | 2.1 |
Aristo Bio-Tech and Lifescience Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 1,552,159,000.0 | 1,406,239,000.0 | 1,272,870,000.0 | 998,292,000.0 | — |
| Total Liabilities | 1,111,104,000.0 | 1,032,926,000.0 | 936,784,000.0 | 696,739,000.0 | — |
| Total Equity | 441,055,000.0 | 373,313,000.0 | 336,086,000.0 | 301,553,000.0 | — |
Owes vs Owns
Aristo Bio-Tech and Lifescience Limited owed ₹0.72 for every ₹1 it owned in Mar 2026, up from ₹0.70 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.72× | 0.73× | 0.74× | 0.70× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Aristo Bio-Tech and Lifescience Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 1.7%Receivables 35.3%Inventory 40.7%Fixed assets (tangible) 15.2%Other assets 7.1%
How it's funded — Mar 2026
Short-term debt 17.9%Long-term debt 4.9%Payables 45.6%Other liabilities 3.1%Shareholders' equity 28.4%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2.6 | 1.1 | 0.6 | 1.8 |
| Receivables | 54.7 | 56.2 | 57.5 | 44.6 |
| Inventory | 63.2 | 47.4 | 40.2 | 30.8 |
| Fixed assets (tangible) | 23.6 | 24.0 | 21.8 | 16.7 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 11.0 | 11.9 | 7.2 | 5.9 |
| Liabilities & equity | ||||
| Short-term debt | 27.8 | 14.2 | 10.9 | 12.3 |
| Long-term debt | 7.6 | 7.6 | 10.0 | 10.2 |
| Payables | 70.9 | 78.4 | 69.5 | 45.4 |
| Other liabilities | 4.9 | 3.0 | 3.3 | 1.8 |
| Shareholders' equity | 44.1 | 37.3 | 33.6 | 30.2 |
| Net tangible assets | 44.1 | 37.3 | 33.6 | 30.2 |
Aristo Bio-Tech and Lifescience Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 88,529,000.0 | 100,167,000.0 | 76,004,000.0 | -27,836,000.0 | — |
| Investing Activities | -29,700,000.0 | -51,468,000.0 | -66,096,000.0 | -37,456,000.0 | — |
| Financing Activities | -43,719,000.0 | -43,914,000.0 | -22,066,000.0 | 79,657,000.0 | — |